Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells

BMC Medical Genomics

Volumn 2, Issue , 2009, Pages

  Zhao, Hongjuan ^a   Flamand, Vincent ^a   Peehl, Donna M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; CELL PROTEIN; CLORGYLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; POLYCOMB GROUP PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 69949117553     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-2-55     Document Type: Article

References (46)

1. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. DF Gleason GT Mellinger, J Urol 1974 111 1 58 64
2. Gleason grading and prognostic factors in carcinoma of the prostate. PA Humphrey, Mod Pathol 2004 17 3 292 306
3. Biological determinants of cancer progression in men with prostate cancer. TA Stamey JE McNeal CM Yemoto BM Sigal IM Johnstone, Jama 1999 281 15 1395 1400
4. Monoamine oxidase: from genes to behavior. JC Shih K Chen MJ Ridd, Annu Rev Neurosci 1999 22 197 217
5. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. L True I Coleman S Hawley CY Huang D Gifford R Coleman TM Beer E Gelmann M Datta E Mostaghel B Knudsen P Lange R Vessella D Lin L Hood PS Nelson, Proc Natl Acad Sci USA 2006 103 29 10991 10996
6. Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. H Zhao R Nolley Z Chen SW Reese DM Peehl, Differentiation 2008 76 7 820 30
7. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. SH Chiou HH Ku TH Tsai HL Lin LH Chen CS Chien LL Ho CH Lee YL Chang, Br J Pharmacol 2006 148 5 587 598
8. Crystallization and preliminary crystallographic analysis of rat monoamine oxidase A complexed with clorgyline. J Ma F Kubota M Yoshimura E Yamashita A Nakagawa A Ito T Tsukihara, Acta Crystallogr D Biol Crystallogr 2004 60 Pt 2 317 319
9. The Significance of Monoamine Oxidase-A Expression in High Grade Prostate Cancer. DM Peehl M Coram H Khine S Reese R Nolley H Zhao, Journal of Urology 2008 180 5 2206 11
10. Natural history of progression after PSA elevation following radical prostatectomy. CR Pound AW Partin MA Eisenberger DW Chan JD Pearson PC Walsh, Jama 1999 281 17 1591 1597
11. The therapeutic potential of monoamine oxidase inhibitors. MB Youdim D Edmondson KF Tipton, Nat Rev Neurosci 2006 7 4 295 30916552415
12. Growth of prostatic epithelial and stromal cells in vitro. DM Peehl, Methods Mol Med 2003 81 41 57
13. Comparison of different labeling methods for two-channel high-density microarray experiments. E Manduchi LM Scearce JE Brestelli GR Grant KH Kaestner CJ Stoeckert Jr, Physiol Genomics 2002 10 3 169 179 12209019
14. The Stanford Microarray Database. G Sherlock T Hernandez-Boussard A Kasarskis G Binkley JC Matese SS Dwight M Kaloper S Weng H Jin CA Ball MB Eisen PT Spellman PO Brown D Botstein JM Cherry, Nucleic Acids Res 2001 29 1 152 155
15. Significance analysis of microarrays applied to the ionizing radiation response. VG Tusher R Tibshirani G Chu, Proc Natl Acad Sci USA 2001 98 9 5116 5121
16. Protection from MPTP-induced neurotoxicity in differentiating mouse N2a neuroblastoma cells. LA De Girolamo AJ Hargreaves EE Billett, J Neurochem 2001 76 3 650 660
17. Dopamine and glutamate neurotoxicity in cultured chick telencephali cells: effects of NMDA antagonists, antioxidants and MAO inhibitors. SO Jacobsson CJ Fowler, Neurochem Int 1999 34 1 49 62
18. L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. AN Basma EJ Morris WJ Nicklas HM Geller, J Neurochem 1995 64 2 825 832
19. Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. CJ Creighton, PLoS ONE 2008 3 3 e1816
20. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. K Aoki MM Taketo, J Cell Sci 2007 120 Pt 19 3327 333517881494
21. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. TM Murphy AS Perry M Lawler, Endocr Relat Cancer 2008 15 1 11 25
22. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. AH Bild G Yao JT Chang Q Wang A Potti D Chasse MB Joshi D Harpole JM Lancaster A Berchuck JA Olson Jr JR Marks HK Dressman M West JR Nevins, Nature 2006 439 7074 353 357
23. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. SE DePrimo M Diehn JB Nelson RE Reiter J Matese M Fero R Tibshirani PO Brown JD Brooks, Genome Biol 2002 3 7 RESEARCH0032
24. Characterization of prostate cell types by CD cell surface molecules. AY Liu LD True, Am J Pathol 2002 160 1 37 43
25. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. E Ezhkova HA Pasolli JS Parker N Stokes IH Su G Hannon A Tarakhovsky E Fuchs, Cell 2009 136 6 1122 1135
26. The EZH2 polycomb transcriptional repressor - a marker or mover of metastatic prostate cancer? WR Sellers M Loda, Cancer Cell 2002 2 5 349 350
27. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. J Yu Q Cao R Mehra B Laxman SA Tomlins CJ Creighton SM Dhanasekaran R Shen G Chen DS Morris VE Marquez RB Shah D Ghosh S Varambally AM Chinnaiyan, Cancer Cell 2007 12 5 419 431
28. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. J Yu DR Rhodes SA Tomlins X Cao G Chen R Mehra X Wang D Ghosh RB Shah S Varambally KJ Pienta AM Chinnaiyan, Cancer Res 2007 67 22 10657 10663
29. Role of myosin VI in the differentiation of cochlear hair cells. T Self T Sobe NG Copeland NA Jenkins KB Avraham KP Steel, Dev Biol 1999 214 2 331 341
30. Role of response gene to complement 32 in diseases. SI Vlaicu C Cudrici T Ito M Fosbrink CA Tegla V Rus PA Mircea H Rus, Arch Immunol Ther Exp (Warsz) 2008 56 2 115 122
31. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. G Dobreva M Chahrour M Dautzenberg L Chirivella B Kanzler I Farinas G Karsenty R Grosschedl, Cell 2006 125 5 971 986
32. SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells. X Ouyang M Fujimoto R Nakagawa S Serada T Tanaka S Nomura I Kawase T Kishimoto T Naka, J Cell Physiol 2006 207 2 428 436
33. Human sterile alpha motif domain 9, a novel gene identified as down-regulated in aggressive fibromatosis, is absent in the mouse. CF Li JR MacDonald RY Wei J Ray K Lau C Kandel R Koffman S Bell SW Scherer BA Alman, BMC Genomics 2007 8 92
34. Wnt signalling and prostate cancer. GW Yardy SF Brewster, Prostate Cancer Prostatic Dis 2005 8 2 119 126
35. Beta-catenin signaling in prostate cancer: an early perspective. DR Chesire WB Isaacs, Endocr Relat Cancer 2003 10 4 537 560
36. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. IK Mellinghoff I Vivanco A Kwon C Tran J Wongvipat CL Sawyers, Cancer Cell 2004 6 5 517 527
37. Molecular determinants of resistance to antiandrogen therapy. CD Chen DS Welsbie C Tran SH Baek R Chen R Vessella MG Rosenfeld CL Sawyers, Nat Med 2004 10 1 33 39
38. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. R Chmelar G Buchanan EF Need W Tilley NM Greenberg, Int J Cancer 2007 120 4 719 73317163421
39. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. HV Heemers DJ Tindall, Endocr Rev 2007 28 7 778 808
40. Molecular regulation of androgen action in prostate cancer. SM Dehm DJ Tindall, J Cell Biochem 2006 99 2 333 344
41. Cell differentiation lineage in the prostate. Y Wang S Hayward M Cao K Thayer G Cunha, Differentiation 2001 68 4-5 270 279
42. Stem/progenitor and intermediate cell types and the origin of human prostate cancer. EJ Tokar BB Ancrile GR Cunha MM Webber, Differentiation 2005 73 9-10 463 473
43. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. R Berger PG Febbo PK Majumder JJ Zhao S Mukherjee S Signoretti KT Campbell WR Sellers TM Roberts M Loda TR Golub WC Hahn, Cancer Res 2004 64 24 8867 8875
44. Contribution of the androgen receptor to prostate cancer predisposition and progression. G Buchanan RA Irvine GA Coetzee WD Tilley, Cancer Metastasis Rev 2001 20 3-4 207 223 (Pubitemid 34595269)
45. Androgen receptor in prostate cancer. CA Heinlein C Chang, Endocr Rev 2004 25 2 276 308
46. A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. TH Li H Zhao Y Peng J Beliakoff JD Brooks Z Sun, Nucleic Acids Res 2007 35 8 2767 2776